Xuanzhu Biopharmaceutical Co., Ltd. (02575)
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenal ulcer, adult reflux esophagitis, pylori eradication; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer, R+/HER2- locally advanc
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
